Skip to main content
Erschienen in:
Buchtitelbild

2019 | Mammakarzinom | OriginalPaper | Buchkapitel

1. Maligne Tumoren der Mamma

verfasst von : Christian Schem, Walter Jonat, Nicolai Maass

Erschienen in: Praxisbuch Gynäkologische Onkologie

Verlag: Springer Berlin Heidelberg

Zusammenfassung

In dem Kapitel Maligne Tumoren der Mamma wird die Pathologie, Diagnostik und Therapie der Erkrankung umfassend beschrieben. Von der Klassifikation der Erkrankung bis hin zu modernen OP-Techniken und der Planung der Therapie in Bezug auf die unterschiedlichen intrinsischen Subtypen des Mammakarzinoms bietet dieses Kapitel einen guten Überblick über den Goldstandard in der Behandlung. Darüber hinaus werden zukunftsweisende Behandlungsstrategien und Medikationen aus der aktuellen Diskussion und Wissenschaft wiedergegeben. Das Kapitel eignet sich nicht nur für das Studium, sondern stellt ebenso ein Nachschlagewerk für den Arzt bzw. die Ärztin in der Weiterbildung dar. Die Literatur wurde umfangreich aktualisiert und bietet somit die Möglichkeit, in das tiefere Studium dieser Erkrankung einzusteigen.
Literatur
Zurück zum Zitat Aberzk WJ, Siver B, Henderson IC, Cady B, Harris JR (1986) The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58:1214–1218CrossRef Aberzk WJ, Siver B, Henderson IC, Cady B, Harris JR (1986) The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 58:1214–1218CrossRef
Zurück zum Zitat Adzersen KH, Gerhard I (2001) Phytoöstrogene und Brustkrebs – Senken Pflanzenöstrogene das Risiko? Geburtshilfe Frauenheilkd 61:234–241 Adzersen KH, Gerhard I (2001) Phytoöstrogene und Brustkrebs – Senken Pflanzenöstrogene das Risiko? Geburtshilfe Frauenheilkd 61:234–241
Zurück zum Zitat Aebi S, Gelber S, Lang I, Anderson S, Robidoux A, Martin M et al (2012) Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial. Cancer Res 72 (24 Suppl) 96s (Abstr. S3-2)CrossRef Aebi S, Gelber S, Lang I, Anderson S, Robidoux A, Martin M et al (2012) Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial. Cancer Res 72 (24 Suppl) 96s (Abstr. S3-2)CrossRef
Zurück zum Zitat Armstrong K, Moye E, Wiliams S, Berlin JA, Reynolds EE (2007) Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 146:516–526CrossRef Armstrong K, Moye E, Wiliams S, Berlin JA, Reynolds EE (2007) Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 146:516–526CrossRef
Zurück zum Zitat ATAC Trialists Group (2008) Effect of anastrazole and tamoxifen as adjuvant treatment for early breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef ATAC Trialists Group (2008) Effect of anastrazole and tamoxifen as adjuvant treatment for early breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53CrossRef
Zurück zum Zitat Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144CrossRef Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138–1144CrossRef
Zurück zum Zitat BIG 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRef BIG 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757CrossRef
Zurück zum Zitat Bilchert-Toft M, Smola MG, CataliottiL O’Higgins N (1997) Principles and guidelines for surgeons – management of symptomatic breast cancer. European Society of Surgical Oncology. Eur J Surg 23:101–109CrossRef Bilchert-Toft M, Smola MG, CataliottiL O’Higgins N (1997) Principles and guidelines for surgeons – management of symptomatic breast cancer. European Society of Surgical Oncology. Eur J Surg 23:101–109CrossRef
Zurück zum Zitat Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130CrossRef Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130CrossRef
Zurück zum Zitat Bonnier P, Romain S, Dilhuydy JM et al (1997) Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 4:720–727CrossRef Bonnier P, Romain S, Dilhuydy JM et al (1997) Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 4:720–727CrossRef
Zurück zum Zitat Bratthauer GL, Tavassoli FA (2002) Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clincal implications. Virchows Arch 440:134–138CrossRef Bratthauer GL, Tavassoli FA (2002) Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clincal implications. Virchows Arch 440:134–138CrossRef
Zurück zum Zitat Brown JE, Coleman RE (2003) Metastatic bone disease: developing strategies to optimize management. Am J Can 2:269–281CrossRef Brown JE, Coleman RE (2003) Metastatic bone disease: developing strategies to optimize management. Am J Can 2:269–281CrossRef
Zurück zum Zitat Brufsky A, Rivera R, Hurvitz A et al (2010) Progression-free survival in patient subgroups in RIBBON-2, a phase II trial of chemotherapy plus or minus bevacizumab for second-line treatment of Her2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 28 (Suppl) Abstr. 1021 Brufsky A, Rivera R, Hurvitz A et al (2010) Progression-free survival in patient subgroups in RIBBON-2, a phase II trial of chemotherapy plus or minus bevacizumab for second-line treatment of Her2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 28 (Suppl) Abstr. 1021
Zurück zum Zitat Buchholz TA, Katz A, Strom EA et al (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53:880–888CrossRef Buchholz TA, Katz A, Strom EA et al (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53:880–888CrossRef
Zurück zum Zitat Calabrese C, Distante V, Orzalesi L et al (2001) Immediate reconstruction with mammaplasty in conservative breast cancer treatment: long-term results. Focus Rec Breast Cancer Surg Osp Ital Chir 7:38–46 Calabrese C, Distante V, Orzalesi L et al (2001) Immediate reconstruction with mammaplasty in conservative breast cancer treatment: long-term results. Focus Rec Breast Cancer Surg Osp Ital Chir 7:38–46
Zurück zum Zitat Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092CrossRef Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092CrossRef
Zurück zum Zitat Coombes R, Kilburn L, Snowdown C (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570CrossRef Coombes R, Kilburn L, Snowdown C (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570CrossRef
Zurück zum Zitat Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M. Piccart-Gebhart M et al (2017) St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. An Oncol 28(8, 1 August):1700–1712 https://doi.org/10.1093/annonc/mdx308CrossRef Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan M. Piccart-Gebhart M et al (2017) St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. An Oncol 28(8, 1 August):1700–1712 https://​doi.​org/​10.​1093/​annonc/​mdx308CrossRef
Zurück zum Zitat Dunne C, Burke JP, Morrow M, Kell MR (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27:1615–1620CrossRef Dunne C, Burke JP, Morrow M, Kell MR (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27:1615–1620CrossRef
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 335:1444–1455 Early Breast Cancer Trialists’ Collaborative Group (1995) Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med 335:1444–1455
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer. Overview of randomized trials. Lancet 348:1189–1198CrossRef Early Breast Cancer Trialists’ Collaborative Group (1996) Ovarian ablation in early breast cancer. Overview of randomized trials. Lancet 348:1189–1198CrossRef
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 355:1757–1770CrossRef Early Breast Cancer Trialists’ Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 355:1757–1770CrossRef
Zurück zum Zitat Early Breast Cancer Trialists’ Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
Zurück zum Zitat Ellis MJ, Hayes DF, Lippmann ME (2000) Treatment of metastatic breast cancer. Cancer 2000:749–797 Ellis MJ, Hayes DF, Lippmann ME (2000) Treatment of metastatic breast cancer. Cancer 2000:749–797
Zurück zum Zitat Faverly DR, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in clinical implications. Semin Diagn Pathol 11:193–198PubMed Faverly DR, Burgers L, Bult P, Holland R (1994) Three dimensional imaging of mammary ductal carcinoma in clinical implications. Semin Diagn Pathol 11:193–198PubMed
Zurück zum Zitat Fisher B, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World J Surg 18:63–69CrossRef Fisher B, Anderson S (1994) Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. World J Surg 18:63–69CrossRef
Zurück zum Zitat Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M (1981) The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic and nodal status in carcinoma of the breast cancer. Surg Gynecol Obstet 152:765–772PubMed Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M (1981) The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic and nodal status in carcinoma of the breast cancer. Surg Gynecol Obstet 152:765–772PubMed
Zurück zum Zitat Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up a randomized trial comparing total mastectomy, lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241CrossRef Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up a randomized trial comparing total mastectomy, lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241CrossRef
Zurück zum Zitat Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncol 16:3439–3460CrossRef Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31510 women. J Clin Oncol 16:3439–3460CrossRef
Zurück zum Zitat Geyer C, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for her2-positive advanced breast cancer. N Engl J Med 355:2733–2743CrossRef Geyer C, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for her2-positive advanced breast cancer. N Engl J Med 355:2733–2743CrossRef
Zurück zum Zitat Gnant M, Mlineritsch B, Stoeger H et al, Austrian Breast and Colorectal Cancer Study Group (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631–641 https://doi.org/10.1016/s1470-2045(11)70122-x. (Epub 2011 Jun 5)CrossRef Gnant M, Mlineritsch B, Stoeger H et al, Austrian Breast and Colorectal Cancer Study Group (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631–641 https://​doi.​org/​10.​1016/​s1470-2045(11)70122-x. (Epub 2011 Jun 5)CrossRef
Zurück zum Zitat Goldhirsch A, Wood W, Gelber R et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144CrossRef Goldhirsch A, Wood W, Gelber R et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144CrossRef
Zurück zum Zitat Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early-stage breast cancer. N Engl J Med 349:1793–1802CrossRef Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen for early-stage breast cancer. N Engl J Med 349:1793–1802CrossRef
Zurück zum Zitat Guinee VF, Olsson H, Moller T et al (1994) Effect of pregnancy on prognosis for young women with breast cancer. Lancet 343:1587–1589CrossRef Guinee VF, Olsson H, Moller T et al (1994) Effect of pregnancy on prognosis for young women with breast cancer. Lancet 343:1587–1589CrossRef
Zurück zum Zitat Haffty BG, Fischer D, Beinfield M, Mckhann C (1991) Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21:293–298CrossRef Haffty BG, Fischer D, Beinfield M, Mckhann C (1991) Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21:293–298CrossRef
Zurück zum Zitat Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with family history of breast cancer. N Engl J Med 340:77–84CrossRef Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with family history of breast cancer. N Engl J Med 340:77–84CrossRef
Zurück zum Zitat Henderson IC, Berry DA, Demetri GD et al (2001) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983CrossRef Henderson IC, Berry DA, Demetri GD et al (2001) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983CrossRef
Zurück zum Zitat Hortobagyi GM, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507CrossRef Hortobagyi GM, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507CrossRef
Zurück zum Zitat Hoskin PJ, Yarnold JR, Roos DR, Bentzen S (2001) Second workshop on palliative radiotherapy and symptom control: radiotherapy for bone metastases. Clin Oncol 13:88–90 Hoskin PJ, Yarnold JR, Roos DR, Bentzen S (2001) Second workshop on palliative radiotherapy and symptom control: radiotherapy for bone metastases. Clin Oncol 13:88–90
Zurück zum Zitat Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms (2012) AWMF-Register-Nummer: 032 – 045OL. Kurzversion 3.0. Juli 2012 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms (2012) AWMF-Register-Nummer: 032 – 045OL. Kurzversion 3.0. Juli 2012
Zurück zum Zitat Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrazole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462CrossRef Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrazole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462CrossRef
Zurück zum Zitat Kaufmann M, Costa SD, Scharl A (Hrsg) (2003) Die Gynäkologie. Springer, Berlin Kaufmann M, Costa SD, Scharl A (Hrsg) (2003) Die Gynäkologie. Springer, Berlin
Zurück zum Zitat Keck C, Tempfer C (2002) Hormonersatztherapie bei Frauen nach Brustkrebserkrankung. Geburtshilfe Frauenheilkd 62:1053–1059CrossRef Keck C, Tempfer C (2002) Hormonersatztherapie bei Frauen nach Brustkrebserkrankung. Geburtshilfe Frauenheilkd 62:1053–1059CrossRef
Zurück zum Zitat Keck C, Tempfer C (2003) Hormonsubstitution und Mammakarzinomscreening. Geburtshilfe Frauenheilkd 63:999–1003CrossRef Keck C, Tempfer C (2003) Hormonsubstitution und Mammakarzinomscreening. Geburtshilfe Frauenheilkd 63:999–1003CrossRef
Zurück zum Zitat Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353CrossRef Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353CrossRef
Zurück zum Zitat Köchli OR, Sevin BU, Benz J, Petru E (1998) Gynäkologische Onkologie. Springer, BerlinCrossRef Köchli OR, Sevin BU, Benz J, Petru E (1998) Gynäkologische Onkologie. Springer, BerlinCrossRef
Zurück zum Zitat Koscielny S, Tubiana M (1999) The link between local recurrence and distant metastases in breast cancer. Int J Radiat Oncol Biol Phys 43:245–246CrossRef Koscielny S, Tubiana M (1999) The link between local recurrence and distant metastases in breast cancer. Int J Radiat Oncol Biol Phys 43:245–246CrossRef
Zurück zum Zitat Kreipe HH (2012) Translationale Forschung und Diagnostik beim Mammakarzinom. Pathologe 33(Suppl 2):282–290CrossRef Kreipe HH (2012) Translationale Forschung und Diagnostik beim Mammakarzinom. Pathologe 33(Suppl 2):282–290CrossRef
Zurück zum Zitat Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M (1997) Time since childbirth and prognosis in primary breast cancer: population based study. Int J Cancer 72:720–727CrossRef Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M (1997) Time since childbirth and prognosis in primary breast cancer: population based study. Int J Cancer 72:720–727CrossRef
Zurück zum Zitat Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609–618CrossRef Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14:609–618CrossRef
Zurück zum Zitat Lagios MD, Westdahl PR, Margolin FR, Rose MR (1982) Ductal carcinoma in situ. Relationship or extent of noninvasive to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 50:1309–1314CrossRef Lagios MD, Westdahl PR, Margolin FR, Rose MR (1982) Ductal carcinoma in situ. Relationship or extent of noninvasive to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 50:1309–1314CrossRef
Zurück zum Zitat Levine MN, Bramwell VH, Pritchard KI et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 16:2651–2658CrossRef Levine MN, Bramwell VH, Pritchard KI et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 16:2651–2658CrossRef
Zurück zum Zitat LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723CrossRef LHRH-agonists in Early Breast Cancer Overview group (2007) Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711–1723CrossRef
Zurück zum Zitat Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastastic breast cancer. N Engl J Med 357:2666–2676CrossRef Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastastic breast cancer. N Engl J Med 357:2666–2676CrossRef
Zurück zum Zitat Moebus V, Jackisch C, Lueck HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28:2874–2880CrossRef Moebus V, Jackisch C, Lueck HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28:2874–2880CrossRef
Zurück zum Zitat Niemeyer M, Paepke S, Schmied R et al (2009) Subcutaneous mastectomy including skin conservation of the nipple areola complex: broadening the indications. Cancer Res 69(Suppl) Abstr. 3107CrossRef Niemeyer M, Paepke S, Schmied R et al (2009) Subcutaneous mastectomy including skin conservation of the nipple areola complex: broadening the indications. Cancer Res 69(Suppl) Abstr. 3107CrossRef
Zurück zum Zitat Noguchi M, Fukushima W, Ohta N et al (1992) Oncological aspects of immediate breast reconstruction im mastectomy patients. J Surg Oncol 50:241–246CrossRef Noguchi M, Fukushima W, Ohta N et al (1992) Oncological aspects of immediate breast reconstruction im mastectomy patients. J Surg Oncol 50:241–246CrossRef
Zurück zum Zitat O’Shaughnessy J, Dieras V, Glaspy J et al (2009) Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Res 69(Suppl) Abstr. 207CrossRef O’Shaughnessy J, Dieras V, Glaspy J et al (2009) Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Res 69(Suppl) Abstr. 207CrossRef
Zurück zum Zitat Paradiso A, Schittuli F, Cellamare G et al (2001) Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferation, node-negative breast cancer. J Clin Oncol 19:3929–3937CrossRef Paradiso A, Schittuli F, Cellamare G et al (2001) Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferation, node-negative breast cancer. J Clin Oncol 19:3929–3937CrossRef
Zurück zum Zitat Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479CrossRef Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479CrossRef
Zurück zum Zitat Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prevention and observation of surgical end points study group. N Engl J Med 346:1616–1622CrossRef Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prevention and observation of surgical end points study group. N Engl J Med 346:1616–1622CrossRef
Zurück zum Zitat Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229–238CrossRef Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229–238CrossRef
Zurück zum Zitat Robson M, Im S, Senkus E, Xu B, Domchek S, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRef Robson M, Im S, Senkus E, Xu B, Domchek S, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRef
Zurück zum Zitat Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 336:1465–1471CrossRef Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis – effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 336:1465–1471CrossRef
Zurück zum Zitat Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressmann PI (2000) Consensus Conference on the Treatment of In Situ Ductal Carcinoma in the Breast, April 22–25, 1999. Cancer 15:946–954 Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressmann PI (2000) Consensus Conference on the Treatment of In Situ Ductal Carcinoma in the Breast, April 22–25, 1999. Cancer 15:946–954
Zurück zum Zitat Silverstein MJ, Craig PH, Lagios MD et al (1996) Developing a prognostic index for ductal carcinoma in situ of breast. Cancer 78:1138–1140CrossRef Silverstein MJ, Craig PH, Lagios MD et al (1996) Developing a prognostic index for ductal carcinoma in situ of breast. Cancer 78:1138–1140CrossRef
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 3444:783–792CrossRef Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 3444:783–792CrossRef
Zurück zum Zitat Smith I, Procter M, Gelber R et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369:29–36CrossRef Smith I, Procter M, Gelber R et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 369:29–36CrossRef
Zurück zum Zitat Solin L, Orel S, Hwang W et al (2008) Relationship of breast magnetic resonance imaging after breast conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26:386–391CrossRef Solin L, Orel S, Hwang W et al (2008) Relationship of breast magnetic resonance imaging after breast conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 26:386–391CrossRef
Zurück zum Zitat Stadtmauer EA, O’Neill A, Goldstein LJ et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342:1069–1076CrossRef Stadtmauer EA, O’Neill A, Goldstein LJ et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342:1069–1076CrossRef
Zurück zum Zitat The ATAC Trialists Group (2003) Anastozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC Trial Efficacy and Safety Update Analysis. Cancer 98:1802–1810CrossRef The ATAC Trialists Group (2003) Anastozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC Trial Efficacy and Safety Update Analysis. Cancer 98:1802–1810CrossRef
Zurück zum Zitat Thürlimann B (2005) BIG-1–98. A prospective randomized phase III study to evaluate letrozol as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 14:4CrossRef Thürlimann B (2005) BIG-1–98. A prospective randomized phase III study to evaluate letrozol as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 14:4CrossRef
Zurück zum Zitat Tran NV, Chang DW, Gupta A, Kroll SS, Robb GL (2001) Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 108:78–82CrossRef Tran NV, Chang DW, Gupta A, Kroll SS, Robb GL (2001) Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 108:78–82CrossRef
Zurück zum Zitat Tutt A, Robson M, Garber J et al (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet 376:235–244CrossRef Tutt A, Robson M, Garber J et al (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet 376:235–244CrossRef
Zurück zum Zitat Vandeweyer E, Deraemaecker R, Nogaret JM, Hertens D (2000) Institution immediate breast reconstruction with implants and adjuvant chemotherapy: a good option? Eur J Cancer 36(Suppl 5):59 Vandeweyer E, Deraemaecker R, Nogaret JM, Hertens D (2000) Institution immediate breast reconstruction with implants and adjuvant chemotherapy: a good option? Eur J Cancer 36(Suppl 5):59
Zurück zum Zitat Vandeweyer E, Hertens D, Nogaret JM, Deraemaecker R (2001) Immediate breast reconstruction with saline filled implants: no Interference with the oncologic outcome? Plast Reconstr Surg 107:1409–1412CrossRef Vandeweyer E, Hertens D, Nogaret JM, Deraemaecker R (2001) Immediate breast reconstruction with saline filled implants: no Interference with the oncologic outcome? Plast Reconstr Surg 107:1409–1412CrossRef
Zurück zum Zitat Van Teinhoven G, Voogd AC, Peterse JL et al (1999) Prognosis after treatment for loco-regional recurrence after mastectomy and breast-conserving therapy in two randomised studies (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish BREast Cancer Cooperative Group. Eur J Cancer 35:32–38CrossRef Van Teinhoven G, Voogd AC, Peterse JL et al (1999) Prognosis after treatment for loco-regional recurrence after mastectomy and breast-conserving therapy in two randomised studies (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish BREast Cancer Cooperative Group. Eur J Cancer 35:32–38CrossRef
Zurück zum Zitat Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1232–1277CrossRef Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1232–1277CrossRef
Zurück zum Zitat Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553CrossRef Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546–553CrossRef
Zurück zum Zitat Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688–1697CrossRef Voogd AC, Nielsen M, Peterse JL et al (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19:1688–1697CrossRef
Zurück zum Zitat Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML (2000) Does locoregional radiation therapy improve survival in breast cancer? A metaanalysis. J Clin Oncol 18:1220–1229CrossRef Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML (2000) Does locoregional radiation therapy improve survival in breast cancer? A metaanalysis. J Clin Oncol 18:1220–1229CrossRef
Zurück zum Zitat Wittekind C (Hrsg) (2017) TNM Klassifikation maligner Tumoren, 8. Aufl. Wiley-VCH, Weinheim Wittekind C (Hrsg) (2017) TNM Klassifikation maligner Tumoren, 8. Aufl. Wiley-VCH, Weinheim
Metadaten
Titel
Maligne Tumoren der Mamma
verfasst von
Christian Schem
Walter Jonat
Nicolai Maass
Copyright-Jahr
2019
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-57430-0_1

Passend zum Thema

ANZEIGE

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

ANZEIGE

Neue 5-Jahres-Daten der monarchE Studie zur adjuvanten Brustkrebstherapie

Abemaciclib [1,a] ist in Kombination mit einer endokrinen Therapie (ET) zur adjuvanten Behandlung des HR+, HER2- Mammakarzinoms mit hohem Rezidivrisiko# indiziert. Auf dem ESMO 2023 wurden nun neue Follow-Up Daten der Zulassungsstudie vorgestellt, die einen klaren Vorteil der Kombination gegenüber der alleinigen ET auch nach 5 Jahren aufzeigen. [2,3]

ANZEIGE

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom. 
 

Passend zum Thema

ANZEIGE

Bei Immuntherapien das erhöhte Thromboserisiko beachten

Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.

ANZEIGE

CAT-Management ist ganz einfach – oder doch nicht?

Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.

ANZEIGE

Management von Thromboembolien bei Krebspatienten

Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.

Passend zum Thema

DKK 2024
21. - 24. Februar 2024 | Berlin

Kongressdossier zum Deutschen Krebskongress 2024

Erfahren Sie auf dieser Seite, was auf dem DKK 2024 diskutiert wurde. Es ging um den Stellenwert der Künstlichen Intelligenz in der Onkologie, um Innovationen bei Ovarial- und Glioblastom oder die teils gravierenden Nebenwirkungen von Checkpoint-Inhibitoren. Außerdem lesen Sie zu den Dos und Don’ts des molekularpathologischen Befundberichts.

In Kooperation mit:
Deutsche Krebsgesellschaft e. V. und Stiftung Deutsche Krebshilfe

Passend zum Thema

ANZEIGE

Umfrage: Topika mit Dexpanthenol bei Radiodermatitis empfohlen

In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1]. 

ANZEIGE

Handekzem: Adhärenz bei topischer Therapie nicht zufriedenstellend

Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1]. 

ANZEIGE

Bepanthen® unterstützt bei vielen Indikationen die Regeneration der Haut

Content Hub

Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.